Mechanism of Action
Dopamine Release Stimulation
Secretoneurin stimulates dopamine release from striatal neurons and dopaminergic terminals in a calcium-dependent manner. This dopaminergic modulation is independent of conventional neurotransmitter release mechanisms and may contribute to motor function regulation. Secretoneurin levels are reduced in Parkinson disease brains, suggesting a role in dopaminergic circuit maintenance.
Angiogenesis
Secretoneurin is a potent promoter of endothelial cell migration, proliferation, and tube formation. Its angiogenic activity is comparable to VEGF at equimolar concentrations. Secretoneurin activates VEGF receptor signaling and mobilizes endothelial progenitor cells from bone marrow. This activity is being exploited in preclinical models of peripheral arterial disease and myocardial ischemia.
Research Summary
Therapeutic Angiogenesis
PreclinicalIntramuscular secretoneurin gene transfer in rodent and porcine models of critical limb ischemia significantly improves limb perfusion, collateral vessel formation, and muscle function. The angiogenic response is comparable to VEGF gene therapy without the edema and vascular leakage side effects associated with VEGF overexpression.
Cardiac Protection
PreclinicalSecretoneurin administration in myocardial infarction models reduces infarct size and improves cardiac function through angiogenic and anti-apoptotic mechanisms. Plasma secretoneurin levels are elevated following acute MI, suggesting a compensatory angiogenic response.
Calculate your Secretoneurin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Angiogenesis induction | 1-10 nM | Single / repeated | Cell culture / IM injection |
| Dopamine release | 0.1-1 nM | Single | Striatal superfusion |
Preclinical only. No approved human use. Angiogenic gene therapy approach in early clinical development.
Interactions
Safety Profile
Secretoneurin is an endogenous neuropeptide with physiological roles in neurotransmitter regulation and tissue homeostasis. Preclinical angiogenic therapy studies show efficacy without significant toxicity. The lack of vascular leakage side effects compared to VEGF is a potential advantage. Human safety data absent.
References
- [1]Kirchmair R et al. (2004). Secretoneurin, an angiogenic neuropeptide, induces angiogenesis and arteriogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(10), 1892-1898.
- [2]Fischer-Colbrie R et al. (1995). GABA, enkephalin/" class="wiki-internal-link">enkephalin and VIP in adrenal chromaffin cells: gene expression, storage and secretion. Journal of the Autonomic Nervous System, 54(1), 61-66.